ArticleFEBS open bio2026
GelMA-based 3D spheroids recapitulate transcriptomic and functional hallmarks of myeloid sarcoma.
Article in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Myeloid sarcoma (MS) is a rare extramedullary manifestation of acute myeloid leukemia (AML). Conventional two-dimensional cultures fail to replicate the constraints of the MS microenvironment. We demonstrated that 5% gelatin methacrylate (GelMA) hydrogels provide a tunable three-dimensional matrix for in vitro modeling of MS. GelMA hydrogels exhibited tissue-like stiffness and oxygen diffusion properties, supporting the formation of viable spheroids from myeloid leukemia cell lines. The 3D context induced G1 cell cycle arrest and apoptotic progression, reflecting dormancy at extramedullary sites. RNA sequencing revealed transcriptional reprogramming in GelMA-embedded spheroids, with an enrichment in ECM remodeling and metabolic pathways. Furthermore, transcriptomic profiles from 3D-cultured cells aligned with patient-derived MS samples, validating the model's relevance to MS. Thus, we present a GelMA-based system which provides a clinically relevant platform for investigating MS biology and screening potential therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.